welcome to

the 11th ILANIT/FISEB Conference

Monday - Thursday, 23-26 February 2026, Eilat

Welcome to

The 11th ILANIT/FISEB Conference

Monday - Thursday, 23-26 February 2026, Eilat

Satellite Session

Pediatric Oncology

The session will take place on Thursday afternoon, 26.2.26, 12:00-18:00
* Closed sessions for satellite participants only. Pre-registration is required.

Pediatric Oncology is entering a new era

With the rise of cross-disciplinary innovation, translational pipelines, and collaborative infrastructures, we are witnessing a global shift in how pediatric solid tumors are approached — from bench to bedside and back. This symposium brings together world leaders in pediatric brain tumors and neuroblastoma to explore how investigator-led clinical research can evolve into tangible, impactful clinical tools, platforms, and therapeutic strategies.

What to Expect?

  • Real-case presentations of research-to-clinic pipelines
  • Current preclinical research in Israel: promising leads in Immunotherapy, personalized solutions, nano-delivery and modeling
  • Discussion with international clinical study consortia leaders re translation of current preclinical research to clinical studies
  • Moderated panel on building national infrastructure for pediatric oncology research

Topics to Be Covered

  • Real-world pipelines: from organoids to trials
  • Liquid biopsy and CSF-based biomarkers in pediatric CNS & NB tumors
  • Immunotherapy and personalized therapy in relapsed cases
  • Biobanking, harmonization, and multi-center trial readiness
  • The role of clinicians, researchers, and parents  in shaping actionable projects

Confirmed International Speakers and Participants (to be incorporated throughout the sessions)

  • Chairperson: Michelle Monje (USA) – Translating Neurobiology to Clinical Breakthroughs
Renowned for her work on diffuse midline gliomas and tumor–microenvironment interactions, Prof. Monje leads clinical translation through advanced models, immunotherapy, and global collaboration.
  • Roger Packer (USA) – Therapeutic Innovation in Pediatric CNS Tumors
With decades of leadership in clinical trials and translational strategies, Prof. Packer brings unmatched experience in driving therapy development across CNS tumor subtypes.
  • Praveen Raju (USA) – Drugging the ‘Undruggable’ in Pediatric Neuro-Oncology
A physician-scientist with expertise in GEM models of pediatric brain tumors and CNS drug delivery, Dr. Raju is leveraging novel nanotherapeutic technologies to address the translational challenges in pediatric neuro-oncology.
  • Uri Tabori (Canada) – Genetics and Immunotherapy for Pediatric Brain Tumors
An expert in cancer predisposition and hypermutation, Prof. Tabori integrates genetic diagnostics and immunotherapy into real-world protocols for children with high-risk CNS tumors.
  • Neuroblastoma Leader (TBD) – Emphasis on international preclinical-clinical collaboration.
  • Sabine Mueller (Switzerland) – TBC
Prof. Sabine Mueller is a globally recognized leader in pediatric neuro-oncology, with joint appointments at UCSF, University Children’s Hospital Zurich, and as the Executive Director of the Pacific Pediatric Neuro-Oncology Consortium (PNOC). Her work bridges clinical care, translational research, and global collaboration to improve outcomes for children with brain tumors.
  • John Anderson (UK) – TBC
Prof. John Anderson is a leading clinician-scientist in pediatric oncology and immunotherapy, based at Great Ormond Street Hospital (GOSH) and University College London (UCL). With deep expertise in T-cell and antibody-based therapies for neuroblastoma and other pediatric cancers, his research has pioneered early-phase clinical trials and translational immunotherapy approaches.

Poster Viewing and ARI-PST Consortium Working Meeting

Light lunch alongside moderated poster discussions with promising researchers and clinicians.

ARI-PST Consortium Working Meeting

Invitation-only closed session for consortium partners, researchers, and strategic stakeholders.
Focus: Shared infrastructure, collaborative grants, and 2026–2027 roadmap.

Challenge Pitch Session: “What Needs to Be Solved?”

Hospital-based clinicians will each present a real clinical question that demands a research solution. A short feedback round will follow with current available innovative therapies, followed by future applications of current Israeli cutting edge preclinical research

Clinical Innovation Spotlight

A short showcase presenting pediatric oncology research stories that are on their way (or already made it) into clinical practice:

  • Liquid biopsy in pediatric tumors – from proof to pilot
  • Promising therapies in pediatric brain tumors and neuroblastoma
  • Innovative preclinical studies

Closing Panel: From Research Hubs to Clinical Action

How do we bridge the gap between ideas and impact in pediatric oncology?
This session gathers cross-sector voices to chart the path forward for Israel and beyond, with a focus on real platforms, shared research assets, and clinician-driven innovation.

Key Questions:

  • What platforms are missing in Israel for pediatric clinical research?
  • How can biobanks and real-time data be made more accessible?
  • What are the bottlenecks in moving research into practice?
  • How can national collaboration elevate our global role?

Panelists will include international speakers, Israeli consortium leads, and representatives from the Ministry of Health and family organizations. (4 -5 Panelists).